Frontlight ResearchEarly access
Taking peoplePhase 2
Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy
Key facts
- Who runs it
- Artcline GmbH
- Where
- Germany20 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 142 people, planned
- Started
- 24 Jul 2022
- Planned end
- 30 Jun 2026
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- ARTICE
- Record updated
- 25 May 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 32 criteriaShow less
Who can take part
- Adult subjects; ≥ 18 years of age; with septic shock, defined as those with septic shock according to" Sepsis-3-Definition" who additionally require norepinephrine at a dose of ≥ 0.15 mcg/kg/min (and/or vasopressin at any dose) for a minimum of 6 hours (within the last 48 hours), to maintain a MAP ≥65 mmHg; Subjects ≥ 80 years of age shall have a Clinical Frailty Scale of <5 to be enrolled
- Fulfillment of the definition of septic shock, not longer than 48h before randomization. I.e. the 48h start at the end of the 6h period
- Blood lactate >2 mmol/L despite adequate volume resuscitation during the current sepsis episode
- Source control achieved / in progress in the judgement of the investigator
- Subjects are required to have central venous access and an arterial line, and these are expected to remain present for at least the initial 48 hours of study
- Subjects must have received adequate volume replacement in the judgement of the investigator
- Subject or legal surrogate is willing and able to provide written informed consent and comply with all protocol requirements or confirmation of the urgency of participation in the clinical trial and the possible benefit to the subject by an independent consultant or the implementation of other established procedures according to the local regulations of the contributing centre to include subjects who are unable to provide informed consent
Who cannot take part
- Ongoing (concomitant) or prior within the last 6 month any chemotherapy or radiotherapy for malignancy,
- Previous transplantation,
- Subjects receiving interferon therapy (14 days prior randomisation),
- Suspicion of concomitant acute coronary syndrome based on clinical symptoms and/or ECG within the last 72 hours,
- Previous sepsis with ICU admission within this hospital stay,
- Prior enrolment in the trial,
- Prior use of an investigational medicinal product within the last month OR planned or concurrent participation in a clinical trial for any investigational drug or device,
- Autoimmune disease with systemic medication of ≥10 mg prednisolone equivalent,
- Ischemic stroke or intracranial bleeding within the last 3 months
- Known HIV infection or chronic viral hepatitis,
- Primary cause of hypotension not due to sepsis (e.g. major trauma including traumatic brain injury, haemorrhage, burns, or congestive heart failure/cardiogenic shock),
- Diagnosed and documented pre-existing dementia,
- Severe Covid-Pneumonia
- Bilirubin ≥ 2 mg/dL (≥33 µmol/L),
- Acute or chronic leukemia,
- Acute pulmonary embolism within the last 72 hours,
- Cardiopulmonary resuscitation within last 7 days,
- Moribund subject (life expectancy <72 hours), in the judgement of the investigator
- Presence of a do-not-resuscitate or do-not-intubate order,
- Isolated Urosepsis,
- Pregnancy/nursing period,
- Known/suspected acute mesenteric ischaemia,
- Chronic mechanical ventilation for any reason OR severe COPD requiring either continuous daily oxygen use during the preceding 30 days or mechanical ventilation (for acute exacerbation of COPD) during the preceding 30 days,
- Decision to limit full care taken before obtaining informed consent,
- multiple injuries including polytrauma and burn >20% TBSA (2° or 3°),
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Evaluation of a novel therapy approach for severe sepsis patients. Subjects randomized into the treatment arm receive treatment with an immune cell perfusion system on top of standard care.
Read full original descriptionShow less
This may contribute to the improvement of the impaired organ function of septic shock patients by assisting the impaired immune system (immune competence enhancement = ARTICE)
The 2 groups in the trial
- ARTICE Treatment GroupTreatment being tested
Subjects with septic shock treated with immune cell extracorporeal therapy on top of standard of care
Treatment: ARTICE
- Control GroupNo study treatment, for comparison
Subjects with septic shock receiving standard of care
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 25 May 2025